Genetic and Epigenetic Alterations of Lysophosphatidic Acid Receptor
                    Genes in Rodent Tumors by Experimental Models by Tsujiuchi, Toshifumi et al.
J Toxicol Pathol 2011; 24: 143–148
Review
Genetic and Epigenetic Alterations of Lysophosphatidic Acid 
Receptor Genes in Rodent Tumors by Experimental Models
Toshifumi Tsujiuchi1, Kyoko Okabe1, and Nobuyuki Fukushima2
1  Division of Cancer Biology and Bioinformatics, Department of Life Science, Faculty of Science and Engineering, 
Kinki University, 3-4-1 Kowakae, Higashiosaka, Osaka 577-8502, Japan
2  Division of Molecular Neurobiology, Department of Life Science, Faculty of Science and Engineering,  
Kinki University, 3-4-1 Kowakae, Higashiosaka, Osaka 577-8502, Japan
Abstract: Lysophosphatidic acid (LPA) is a bioactive mediator and induces several biological effects, including cell 
proliferation, migration, morphogenesis and differentiation. LPA interacts with at least six G protein-coupled recep-
tors (GPCRs), including LPA receptor-1 (LPA1), LPA2, LPA3, LPA4, LPA5 and LPA6. These receptors show different 
biological functions through the binding of LPA, depending on the type of cells. In human malignancies, a high level of 
LPA production was found in plasma and ascites in ovarian cancer cases. Moreover, aberrant expression levels of LPA 
receptor genes were detected in some cancer cells. Therefore, it is suggested that LPA receptors may be involved in the 
pathogenesis of tumor cells as well as LPA per se. Recently, we have reported that alterations of LPA receptor genes also 
occur in rodent tumors. In this review, we summarize the recent evidence in the investigations of LPA receptor altera-
tions in rodent tumors by experimental models. (DOI: 10.1293/tox.24.143; J Toxicol Pathol 2011; 24: 143–148)
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Introduction
Lysophosphatidic acid (LPA) is a simple bioactive 
phospholipid consisting of a phosphate, a fatty acid and 
a glycerol1,2. It is present in all mammalian cells and tis-
sues and is detected in serum, plasma, saliva and activated 
platelets1–3. LPA induces several cellular responses, such 
as cell proliferation, differentiation, morphogenesis, cell 
migration, platelet aggregation, secretion of cytokine and 
chemokine and protection from apoptosis1–3. Moreover, it is 
suggested that LPA may be also involved in the develop-
ment of human diseases, including cancers2,4. In fact, a high 
level of LPA production was found in plasma and ascites 
from patients with ovarian cancers, and the plasma levels of 
LPA were also increased in chronic hepatitis C in associa-
tion with liver fibrosis1,5. LPA enhanced malignant abilities 
of tumor cells, including cell growth, migration, invasion, 
production of angiogenic factors and tumorigenicity2,4.
LPA interacts with G protein-coupled receptors (GP-
CRs) to induce various responses. So far, at least six LPA 
receptors have been identified1–4. Previously, aberrant ex-
pressions of LPA receptor genes have been also detected 
in human malignancies, such as ovary, colon and thyroid 
tumors6–9. Moreover, the exogenous LPAR2 or LPAR3-ex-
pressing ovarian cancer cells increased malignant proper-
ties, such as cell migration, invasion and tumorigenicity10. 
Therefore, it has been demonstrated that LPA receptors may 
be involved in the acquisition of malignant potency of tu-
mor cells as well as LPA per se. In our energetic studies, we 
have indicated that mutations and aberrant expressions due 
to DNA methylation of LPA receptor genes occur in rodent 
tumors induced by experimental models. Here, we review 
the current knowledge about LPA receptor gene alterations 
in rodent tumors and suggest an involvement of the LPA 
signaling pathway during carcinogenesis of rodents.
LPA Receptors
LPA acts as a biological mediator binding with LPA 
specific G protein-coupled transmembrane receptors, LPA 
receptors. So far, at least six LPA receptors have been iden-
tified,  including  LPA1/EDG2, LPA2/EDG4, LPA3/EDG7, 
LPA4/P2Y9/GPR23, LPA5/GPR92 and LPA6/P2Y51–4. Addi-
tionally, GPR87 has been proposed as a candidate for a new 
LPA receptor11. LPA receptors couple with individual sets of 
G proteins (Gi, Gq and G12/13) and mediate various biologi-
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cal responses to LPA1–4. The expression patterns of LPA re-
ceptor genes are dependent on the type of cells1. While LPA1 
is ubiquitously expressed in normal tissues, the expressions 
of other LPA receptors are relatively restricted, suggesting 
that these receptors have different biological functions1. For 
example, both LPA1 and LPA2 can couple with Gi, Gq and 
G12/13, and stimulates cell proliferation, phospholipase C 
activation, intracellular calcium mobilization and adenylyl 
cyclase inhibition12. However, some different phenotypes 
of LPA1 and LPA2 have also been found in knockout mice, 
indicating that LPA1 and LPA2, at least in part, possess dis-
tinct functions13. On the other hand, LPA3 couples with Gi 
and Gq, but not G12/13. In recent studies, LPA6/P2Y5 has 
been identified as a causative gene of hair loss14,15 (Fig.1).
Genetic Alterations
Mutations for LPA receptor genes were found in hu-
man colon cancer and osteosarcoma cells16,17. In colon can-
cer cells, 2 out of 6 cells showed LPAR2 and/or LPAR4 gene 
mutations16. LPAR1 and LPAR3 gene mutations occurred in 
one out of two osteosarcoma cells17. In rodent tumors, dif-
ferent patterns and frequencies of LPA receptor gene muta-
tions were also observed.
Mutations of LPA receptor genes in rodent tumors
Lung: A mutation analysis for LPA receptor genes was 
performed using rat lung lesions induced by N-nitrosobis(2-
hydroxypropyl)amine (BHP)18,19. This rat lung carcinogen-
esis model can obtain high yields of adenomatous lesions 
from preneoplastic lesions to carcinomas by continuous oral 
administration of BHP. Although no mutation of the Lpar1 
gene was found in 15 hyperplasias, two out of 12 adeno-
mas (16.7%) showed a TGC to CGC (Cys to Arg) transition 
at codon 24 and a TAT to TAC (Tyr to Tyr) transition at 
codon 292, respectively. Moreover, the Lpar1 gene muta-
tions were detected in 7 out of 17 adenocarcinomas (41.2%). 
In the 7 adenocarcinomas, 3 cases showed an ACT to GCT 
(Thr to Ala) transition at codon 58, a CGG to CAG (Arg to 
Gln) transition at codon 241 and a CCC to TCC (Pro to Ser) 
transition at codon 308. All four other cases showed TTC 
to TCC (Phe to Ser) transitions at codon 295. These results 
suggest that mutations of the Lpar1 gene may be involved 
in the acquisition of growth advantage from adenomas to 
adenocarcinomas during rat lung carcinogenesis induced by 
BHP20. By contrast, no mutation of the Lpar2, Lpar3, Lpar4 
and Lpar5 genes was detected in this model21.
Liver: To evaluate the Lpar1 gene mutation during rat 
liver carcinogenesis, hepatocellular carcinomas (HCCs) 
were induced by exogenous and endogenous liver carcino-
genesis models22–24. For the exogenous model, HCCs were 
induced by N-nitrosodiethylamine (DEN), which is one of 
the most well-known liver carcinogens. On the other hand, 
endogenous carcinogenesis means that tumors are induced 
by endogenous changes that occur without any established 
carcinogen exposure, and prolonged feedings of a choline-
deficient L-amino acid-defined (CDAA) diet can induce rat 
HCCs24. Missense mutations of the Lpar1 gene were de-
tected in 7 out of 15 HCCs (46.7%) induced by DEN . By 
contrast, no mutation of Lpar5 was found in HCCs induced 
by DEN. Five out of 12 HCCs (41.7%) induced by the CDAA 
diet showed missense mutations25. Therefore, it is suggested 
that the Lpar1 mutations may play an important role in the 
development of rat HCCs induced by both liver carcinogen-
esis models.
Pancreas: A number of human pancreatic cancers com-
monly arise from pancreatic duct cells. Hamster pancreatic 
duct adenocarcinomas (PDAs) induced by the rapid produc-
tion model using N-nitrosobis(2-oxopropyl)amine (BOP) 
histologically and genetically resemble the human situa-
tion26,27. In hamster PDAs induced by this model, only one 
out of 10 cases (10%) showed a GGA to GTA (Gly to Val) 
transversion at codon 355 of the Lpar1 gene28. Therefore, 
it seems that the Lpar1 gene mutation may be involved in 
a limited fraction of BOP-induced pancreatic duct carcino-
genesis in hamsters.
Cancer cell lines: No mutation of the Lpar1 gene was 
found in cell lines established from hamster PDAs induced 
by BOP28. In RLCNR rat lung adenocarcinoma cells, COS 
rat osteosarcoma cells, RH7777 rat hepatoma cells, B103 
rat neuroblastoma and C6 glioma cells, no mutation of the 
Lpar5 was detected29 (Table 1).
Location of the Lpar1 gene mutations in rodent tu-
mors
The Lpar1 gene mutations were observed in several 
positions in rodent tumors. Particularly, the frequency of 
missense mutations of codon 295 was high. In lung adeno-
carcinomas induced by BHP, 4 out of 7 mutations were lo-
Fig. 1.  Cellular responses of LPA receptors through the binding of 
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cated at codon 29520. In HCCs induced by exogenous and 
endogenous carcinogenesis, 3 out of 12 mutations were also 
found in codon 29525.  The biological roles of mutations in 
codon 295 are unclear. However, codon 295 is adjacent to 
Lys294, which is one of the critical residues for ligand rec-
ognition or binding in the putative 7th transmembrane do-
main of LPA1
30. Recently, it has been reported that artificial 
replacement of Lys294 with Ala resulted in an enhancement 
of LPA response31. LPA2 and LPA3 contained basic amino 
acids equivalent to Lys294 of LPA1. These amino acids are 
thought to play an important role in LPA binding and the 
subsequent  receptor  activation.  Therefore,  these  findings 
suggest that the mutations in codon 295 of the Lpar1 gene 
might affect the physical properties of the ligand recogni-
tion region in the 7th transmembrane domain, leading to 
changes in affinity of LPA binding or activation of signal-
ing pathways upon LPA stimulation. The locations of Lpar1 
gene mutations in lung, liver and pancreatic tumors of ro-
dents are shown in Fig. 2.
Patterns of the Lpar1 gene mutations in rodent tumors
In tumors induced by nitrosocompounds, the Lpar1 
gene mutation patterns have varied. Among 9 mutations in 
rat lung carcinogenesis model using BHP, 7 cases were T/A 
to C/G transitions and two were G/C to A/T transitions20. In 
DEN-induced rat HCCs, three T/A to C/G transitions, a C/G 
to T/A transition and three G/C to T/A transversions were 
observed25. In hamster PDAs induced by BOP, one mutation 
was a G/C to T/A transversion28. Although G/C to A/T tran-
sition is a common mutation pattern induced by nitrosocom-
pounds32,33, only two lung adenocarcinomas and one HCC 
showed this pattern. By contrast, all 5 mutations in rat HCCs 
by the CDAA diet were T/A to C/G transitions25. Oxy radi-
cal-mediated DNA damage generates several DNA adducts, 
including 8-hydroxyguanine and 8-hydroxyadenine34. It is 
well established that 8-hydroxyguanine induces G/C to T/A 
or A/T to C/G transversions in Escherichia coli35. Moreover, 
8-hydroxyadenine also induces a T/A to C/G transition or an 
A/T to C/G transversion in mammalian cells36,37. Since T/A 
to C/G transition is a frequent pattern, it is suggested that 
the Lpar1 gene may be a target for oxidative DNA damage 
in rodent tumors. In fact, it has been reported that oxidative 
stress is involved in rat hepatocarcinogenesis induced by the 
CDAA diet38.
Epigenetic Alterations
As one of epigenetic mechanisms for the regulation of 
gene expression, DNA methylation of cytosine residues at 
CpG dinucleotides is a strong mediator for the gene silenc-
ing in mammalian genomes39,40. It has been reported that 
loss of tumor suppressor gene expressions is due to aber-
rant DNA methylation of gene promoter regions in several 
tumors39,40. In LPA receptor genes, distinct expression and 
DNA methylation patterns of LPA receptor genes were 
found in human colon cancer cells16. Aberrant DNA meth-
ylation statuses of LPA receptor genes were also detected in 
rodent tumors (Table 2).
Table 1.  Mutations of LPA Receptor Genes in Rodent Tumors
Organs/cells Genes Species Carcinogens/
diets
Lesions/cell types Incidences Ref.
Lung Lpar1 rat BHP adenomas 2/12 (16.7%) (20)
Lpar1 rat BHP adenocarcinomas 7/17 (41.2%) (20)
Lpar2 rat BHP adenocarcinomas 0/15 (0%) (21)
Lpar3 rat BHP adenocarcinomas 0/15 (0%) (21)
Lpar4 rat BHP adenocarcinomas 0/15 (0%) (21)
Lpar5 rat BHP adenocarcinomas 0/15 (0%) (21)
Liver Lpar1 rat DEN HCCs 7/15 (46.7%) (25)
Lpar1 rat CDAA HCCs 5/12 (41.7%) (25)
Lpar5 rat DEN HCCs 0/6 (0%) (27)
Pancreas Lpar1 hamster BOP PDAs 1/10 (10.0%) (28)
Cell line Lpar1 hamster HPD (PDAs) 0/3 (0%) (28)
Fig. 2.  The locations of Lpar1 gene mutations in lung, liver and pancreatic tumors of rodents. EC, extracellular 
domain. TMD, transmembrane domain. IC, intracellular domain.  , rat lung adenomas and adenocarcino-
mas; , rat hepatocellular carcinomas;  , hamster pancreatic duct adenocarcinomas.LPA Receptor Gene Alterations in Rodent Tumors 146
Liver
DNA methylation status and expression levels of the 
Lpar1, Lpar2 and Lpar3 genes were examined in a rat liver 
carcinogenesis model induced by the CDAA diet. The Lpar1 
and Lpar2 genes were unmethylated in the livers of rats fed 
the CDAA diet for 7 days and 2, 12 and 20 weeks, as well as 
in normal liver tissues. In regard to the Lpar3 gene, the liv-
ers at 7 days and 2 and 12 weeks were weakly or moderately 
methylated, and those at 20 weeks were markedly methyl-
ated, while normal liver tissues were unmethylated. More-
over, 4 HCCs induced by the CDAA diet were completely 
methylated. In those samples, the expression levels of the 
Lpar1, Lpa2 and Lpar3 genes were correlated with the DNA 
methylation status41.
In regard to the Lpar5 gene, 4 out of 6 HCCs induced 
by DEN were unmethylated, compared with normal liver 
tissues, which were methylated. These DNA methylation 
patterns were correlated with the Lpar5 gene expression 
levels29.
Lung
In rat normal lung tissues, the Lpar5 gene was not ex-
pressed, and its DNA methylation status was methylated. 
By contrast, 5 out of 6 adenocarcinomas (83.3%) induced 
by BHP indicated increased expressions of Lpar5 with an 
unmethylated status29.
Cancer cell lines
While normal liver and brain tissues expressed the 
Lpar1 gene and its DNA methylation status was unmethyl-
ated, RH7777 and B103 cells showed hypermethylation of 
the Lpar1 gene with elevated expression levels42. In regard 
to the Lpar5 gene, RLCNR and RH7777 cells were unmeth-
ylated compared with normal lung and liver tissues29. In 
mouse tumor cells, aberrant DNA methylation of the Lpar1 
gene was detected in B16F0 melanoma cells, FM3A mam-
mary carcinoma cells and L1210 leukemia cells. The Lpar3 
gene in LL/2 lung tumor cells, B16F0, FM3A and L1210 
cells was also hypermethylated compared with their adja-
cent normal tissues43.
Conclusion
We here reviewed the genetic and epigenetic alterations 
of LPA receptor genes occurring in rodent tumors induced 
by experimental carcinogenesis models and cancer cell 
lines, demonstrating that alterations of the LPA signaling 
pathway may be involved in the development of tumor cells 
in rodents. Our successive study demonstrated that an artifi-
cial mutated form of LPA1 that lacked the carboxyl terminal 
was constitutively active and oncogenic44. Therefore, it is 
suggested that LPA receptors may be one of the important 
molecules for the development of anticancer and chemopre-
vention agents in clinical cancer approaches.
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